Atara Biotherapeutics Inc (ATRA)
10.61
-0.07
(-0.66%)
USD |
NASDAQ |
Nov 21, 16:00
10.60
-0.01
(-0.09%)
After-Hours: 20:00
Atara Biotherapeutics Revenue (Quarterly): 40.19M for Sept. 30, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 40.19M |
| June 30, 2024 | 28.64M |
| March 31, 2024 | 27.36M |
| December 31, 2023 | 4.252M |
| September 30, 2023 | 2.138M |
| June 30, 2023 | 0.957M |
| March 31, 2023 | 1.226M |
| December 31, 2022 | 0.221M |
| Date | Value |
|---|---|
| September 30, 2022 | 4.459M |
| June 30, 2022 | 51.58M |
| March 31, 2022 | 7.314M |
| December 31, 2021 | 7.548M |
| September 30, 2021 | 5.37M |
| June 30, 2021 | 3.87M |
| March 31, 2021 | 3.552M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
0.221M
Minimum
Dec 2022
51.58M
Maximum
Jun 2022
12.58M
Average
4.459M
Median
Sep 2022
Revenue (Quarterly) Benchmarks
| Azenta Inc | 170.06M |
| Perspective Therapeutics Inc | -- |
| Corvus Pharmaceuticals Inc | -- |
| Clearside Biomedical Inc | 1.038M |
| Quanterix Corp | 34.13M |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -21.91M |
| Total Expenses (Quarterly) | 61.95M |
| EPS Diluted (Quarterly) | -2.93 |
| Enterprise Value | -6.078M |
| Gross Profit Margin (Quarterly) | 81.08% |
| Profit Margin (Quarterly) | -54.51% |
| Earnings Yield | -242.8% |
| Normalized Earnings Yield | -242.79 |